EA200801136A1 - Способ лечения фиброзных заболеваний путем индукции иммунологической толерантности - Google Patents

Способ лечения фиброзных заболеваний путем индукции иммунологической толерантности

Info

Publication number
EA200801136A1
EA200801136A1 EA200801136A EA200801136A EA200801136A1 EA 200801136 A1 EA200801136 A1 EA 200801136A1 EA 200801136 A EA200801136 A EA 200801136A EA 200801136 A EA200801136 A EA 200801136A EA 200801136 A1 EA200801136 A1 EA 200801136A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treating
fibrozal
diseases
immunological tolerance
inducing immunological
Prior art date
Application number
EA200801136A
Other languages
English (en)
Other versions
EA015764B1 (ru
Inventor
Арнольд Е. Постлесвайт
Эндрю Х. Канг
Original Assignee
Зе Юниверсити Ов Теннесси Рисеч Фаундэйшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зе Юниверсити Ов Теннесси Рисеч Фаундэйшн filed Critical Зе Юниверсити Ов Теннесси Рисеч Фаундэйшн
Publication of EA200801136A1 publication Critical patent/EA200801136A1/ru
Publication of EA015764B1 publication Critical patent/EA015764B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение впервые продемонстрировало, что пероральное введение коллагена I типа (CI) индуцировало толерантность к CI у пациентов, страдающих от системного склероза (SSc), и облегчало клинические проявления этого заболевания. В соответствии с этим, настоящее изобретение относится к способам лечения фиброзного заболевания путем перорального введения тканевого белка, например коллагена, полученного из ткани, которая подвергается фиброзу.
EA200801136A 2005-11-16 2006-11-16 Способ лечения фиброзных заболеваний путем индукции иммунологической толерантности EA015764B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73719405P 2005-11-16 2005-11-16
PCT/US2006/044344 WO2007059211A2 (en) 2005-11-16 2006-11-16 Methods of treating fibrosing diseases by induction of immune tolerance

Publications (2)

Publication Number Publication Date
EA200801136A1 true EA200801136A1 (ru) 2008-08-29
EA015764B1 EA015764B1 (ru) 2011-12-30

Family

ID=38049272

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801136A EA015764B1 (ru) 2005-11-16 2006-11-16 Способ лечения фиброзных заболеваний путем индукции иммунологической толерантности

Country Status (13)

Country Link
US (3) US7718765B2 (ru)
EP (1) EP1965813A4 (ru)
JP (1) JP2009515983A (ru)
KR (1) KR20080073747A (ru)
CN (1) CN101309694B (ru)
AU (1) AU2006315428B2 (ru)
BR (1) BRPI0618699A2 (ru)
CA (1) CA2627974A1 (ru)
EA (1) EA015764B1 (ru)
HK (1) HK1124260A1 (ru)
IL (1) IL190926A0 (ru)
UA (1) UA93063C2 (ru)
WO (1) WO2007059211A2 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0706575B8 (pt) * 2006-01-13 2021-05-25 Univ Indiana Res & Tech Corp uso colágeno de tipo v ou um componente antigênico do mesmo, e, método para identificar um paciente em espera de transplante de pulmão para um risco aumentado de rejeição de tecido de órgão transplantado.
WO2016076276A1 (ja) * 2014-11-11 2016-05-19 株式会社ニッピ 免疫賦活化剤、細胞性免疫賦活化剤およびｔ細胞数増加剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962025A (en) * 1996-07-16 1999-10-05 The University Of Tennessee Research Corporation Method for treatment of systemic sclerosis and related fibrotic diseases
GB9806806D0 (en) * 1998-03-30 1998-05-27 Univ Cambridge Tech Peptides and uses thereof
US20050197283A1 (en) * 1998-10-04 2005-09-08 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease
JP2001002584A (ja) * 1999-06-15 2001-01-09 Collagen Gijutsu Kenshukai Kk 強皮症の症状改善剤
US20030060438A1 (en) * 2000-08-18 2003-03-27 Henry James L. Oligonucleotides and other modulators of the NK-1 receptor pathway and therapeutic uses thereof
US7037534B2 (en) * 2001-10-24 2006-05-02 Aphios Corporation Inactivation of viral infections agents by chemiluminescence activated light-sensitive compounds
US7544669B2 (en) * 2001-11-21 2009-06-09 The Board Of Trustees Of The Leland Stanford Junior University Polynucleotide therapy
EP1562632B1 (en) * 2002-11-01 2012-12-05 Boys Town National Research Hospital Inducible ligand for alpha1 beta1 integrin and uses
US7854927B2 (en) * 2004-05-11 2010-12-21 Ganeden Biotech, Inc. Methods and compositions for the dietary management of autoimmune disorders
DE102006049185A1 (de) * 2006-10-18 2008-04-24 Bayerl, Thomas M., Prof. Dr. Verwendung von Deuteriumdioxid zur Behandlung von hyperproliferativen Erkrankungen der Haut
WO2009061368A1 (en) * 2007-11-06 2009-05-14 Benaroya Research Institute Inhibition of versican with sirna and other molecules
US20090215708A1 (en) * 2008-02-21 2009-08-27 Bradley Stuart Galer Treatment of Sexual Dysfunction with Proton Pump Agonists
US20130165502A1 (en) * 2008-09-18 2013-06-27 The Ohio State University Diagnostic, Prognostic and Therapeutic Uses of miRs in Adaptive Pathways and Disease Pathways
EP3129768A4 (en) * 2014-04-09 2017-12-06 University of Rochester Method and apparatus to diagnose the metastatic or progressive potential of cancer, fibrosis and other diseases

Also Published As

Publication number Publication date
EP1965813A4 (en) 2012-07-04
CN101309694B (zh) 2012-07-04
BRPI0618699A2 (pt) 2011-09-06
UA93063C2 (ru) 2011-01-10
US7718765B2 (en) 2010-05-18
AU2006315428B2 (en) 2011-12-01
CN101309694A (zh) 2008-11-19
WO2007059211A3 (en) 2007-12-13
JP2009515983A (ja) 2009-04-16
AU2006315428A1 (en) 2007-05-24
EP1965813A2 (en) 2008-09-10
US20140107035A1 (en) 2014-04-17
US20070142286A1 (en) 2007-06-21
EA015764B1 (ru) 2011-12-30
CA2627974A1 (en) 2007-05-24
US20100179096A1 (en) 2010-07-15
IL190926A0 (en) 2009-09-22
HK1124260A1 (en) 2009-07-10
KR20080073747A (ko) 2008-08-11
WO2007059211A2 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
WO2009137217A3 (en) Therapeutic replenishment and enrichment of ocular surface lubrication
EA200800147A1 (ru) Способ получения олмесартан медоксомила
BRPI0517227A (pt) forma de dosagem oral de liberação prolongada do ácido 1-{[alfa-isobutanoiloxietoxi)carbonil]amino metil}-1-cicloexano acético, e, método de tratamento de uma doença ou condição
NO20083793L (no) Antistoffer mot amyloid-beta peptid
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
WO2006037031A3 (en) Formulations and methods for treatment of inflammatory diseases
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
EA200971053A1 (ru) Способы лечения кожных язв
DE60323090D1 (de) 1h-imidazoä4,5-cüchinolinderivate zur behandlung von protein kinase-abhängigen krankheiten
NO20044562L (no) Fremgangsmater for behandling av tarmslyng
BRPI0519124A2 (pt) composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço
EA200901211A1 (ru) Антигены белка с5 и их применение
AU2014340303A1 (en) Tyrosine hydroxylase inhibitors for treating intestinal hyperpermeability
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
CN107835695B (zh) 用于治疗自闭症的组合物和方法
DE60320095D1 (de) Zusammensetzungen zur behandlung von hauterkrankungen
DE69943107D1 (de) Behandlung von autoimmunerkrankungen
RU2011114857A (ru) Композиции и способы лечения расстройств почки
WO2007096396A3 (en) Methods for treating autoimmune or demyelinating diseases
CY1111353T1 (el) Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης
CY1105787T1 (el) Θepαπευτικη αντιμετωπιση η προληψη της ατροφιας του ουροποιογεννητικου συστηματος και τα συμπτωματα της σε γυναικες
EA200970127A1 (ru) Модулятор рецепторов глюкокортикостероидов и способы его применения
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
RU2012136724A (ru) Лечение или профилактика инфекции
EA200501620A1 (ru) Лечение состояний, включающих амилоидные бляшки

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU